Condition: Submucosal Esophageal Adenocarcinoma · Barrett Esophagus · High-risk Mucosal Esophageal Adenocarcinoma · Sponsor: Amsterdam UMC
Aim of this prospective multicenter study is to evaluate the safety of an endoscopic follow-up strategy in patients treated with endoscopic resection (ER) for submucosal or high-risk mucosal esophageal adenocarcinoma (T1bN0M0 or HR T1aN0M0 EAC).
This description comes directly from the study's public registry record.
Vincent Bos, MD · +31204445500 · v.bos@amsterdamumc.nl
Always discuss trial participation with your own doctor first.
| Westmead hospital | Sydney, Australia | Recruiting |
| CUB Hôpital Erasme | Brussels, Belgium | Recruiting |
| AZ Maria Middelares Ghent | Ghent, Belgium | Recruiting |
| UZ Leuven | Leuven, Belgium | Recruiting |
| AZ Delta Roeselare | Roeselare, Belgium | Recruiting |
| Universitätsklinikum Augsburg | Augsburg, Germany | Recruiting |
| EVK Duesseldorf | Düsseldorf, Germany | Recruiting |
| MRI TUM | Münich, Germany | Active Not Recruiting |
| Barmherzige Brüder Regensburg | Regensburg, Germany | Recruiting |
| Amsterdam UMC | Amsterdam, Netherlands | Recruiting |
| Catharina Hospital | Eindhoven, Netherlands | Recruiting |
| University Medical Center Groningen | Groningen, Netherlands | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03222635